$180 Million is the total value of Prosight Management, LP's 34 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 43.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $17,571,000 | -9.3% | 128,000 | -22.2% | 9.75% | -0.3% |
BMY | Sell | BRISTOL-MYERS SQUIBB CO | $15,461,000 | -16.9% | 304,900 | -25.7% | 8.58% | -8.6% |
KURA | Buy | KURA ONCOLOGY INC | $13,473,000 | -21.2% | 888,152 | +2.3% | 7.47% | -13.2% |
QURE | Buy | UNIQURE NV | $12,949,000 | +38.1% | 328,978 | +174.1% | 7.18% | +51.9% |
UTHR | Buy | UNITED THERAPEUTICS CORP | $10,602,000 | +1480.0% | 132,937 | +1445.8% | 5.88% | +1639.9% |
HNGR | Sell | HANGER INC | $8,050,000 | -14.5% | 395,000 | -19.7% | 4.46% | -6.0% |
URGN | Buy | UROGEN PHARMA LTD | $7,754,000 | -17.3% | 325,385 | +24.7% | 4.30% | -9.0% |
ARNA | Sell | ARENA PHARMACEUTICALS INC | $7,467,000 | -22.5% | 163,133 | -0.7% | 4.14% | -14.7% |
CNC | Buy | CENTENE CORP | $7,138,000 | +7.6% | 165,000 | +30.4% | 3.96% | +18.4% |
IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $6,300,000 | -35.8% | 346,149 | -13.5% | 3.50% | -29.3% |
ACIU | Buy | AC IMMUNE SA | $6,180,000 | +97.4% | 1,248,453 | +121.4% | 3.43% | +117.2% |
BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $6,063,000 | +38.3% | 89,952 | +75.7% | 3.36% | +52.1% |
SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $6,011,000 | -24.6% | 2,515,072 | -1.3% | 3.33% | -17.1% |
MGTX | New | MEIRAGTX HOLDINGS PLC | $5,393,000 | – | 338,096 | +100.0% | 2.99% | – |
ALBO | Sell | ALBIREO PHARMA INC | $5,050,000 | -38.2% | 252,500 | -0.3% | 2.80% | -32.0% |
RETA | Sell | REATA PHARMACEUTICALS INC-Acl a | $5,025,000 | -57.4% | 62,591 | -49.9% | 2.79% | -53.1% |
ALDX | Buy | ALDEYRA THERAPEUTICS INC | $4,165,000 | -0.5% | 790,228 | +13.2% | 2.31% | +9.4% |
RCM | New | R1 RCM INC | $3,652,000 | – | 408,958 | +100.0% | 2.03% | – |
HUM | New | HUMANA INC | $3,068,000 | – | 12,000 | +100.0% | 1.70% | – |
ABBV | New | ABBVIE INC | $2,953,000 | – | 39,000 | +100.0% | 1.64% | – |
FIXX | Sell | HOMOLOGY MEDICINES INC | $2,775,000 | -61.6% | 153,303 | -58.5% | 1.54% | -57.7% |
CBIO | Buy | CATALYST BIOSCIENCES INC | $2,741,000 | -32.0% | 558,159 | +2.0% | 1.52% | -25.2% |
GH | New | GUARDANT HEALTH INC | $2,662,000 | – | 41,700 | +100.0% | 1.48% | – |
ARQL | Buy | ARQULE INC | $2,616,000 | +184.0% | 364,797 | +336.0% | 1.45% | +212.7% |
ADMA | Buy | ADMA BIOLOGICS INC | $2,440,000 | +239.4% | 548,409 | +195.3% | 1.35% | +272.7% |
TLGT | Sell | TELIGENT INC | $2,323,000 | +24.2% | 2,446,043 | -17.6% | 1.29% | +36.7% |
CLVS | Buy | CLOVIS ONCOLOGY INC | $2,309,000 | -65.5% | 587,626 | +30.6% | 1.28% | -62.0% |
PSNL | Buy | PERSONALIS INC | $1,691,000 | +10.3% | 115,214 | +104.1% | 0.94% | +21.3% |
CI | Sell | CIGNA CORP | $1,670,000 | -66.1% | 11,000 | -64.8% | 0.93% | -62.7% |
MTEM | Buy | MOLECULAR TEMPLATES INC | $1,470,000 | -11.0% | 222,994 | +12.8% | 0.82% | -2.0% |
New | REATA PHARMACEUTICALS INCcall | $988,000 | – | 12,300 | +100.0% | 0.55% | – | |
UROV | Sell | UROVANT SCIENCES LTD | $972,000 | -13.8% | 102,657 | -28.0% | 0.54% | -5.3% |
SRRA | Sell | SIERRA ONCOLOGY INC | $924,000 | -38.5% | 2,366,707 | -11.7% | 0.51% | -32.2% |
MLND | Sell | MILLENDO THERAPEUTICS INC | $370,000 | -56.7% | 52,051 | -29.5% | 0.20% | -52.4% |
AQXP | Exit | AQUINOX PHARMACEUTICALS INC | $0 | – | -3,637 | -100.0% | -0.01% | – |
KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -34,224 | -100.0% | -0.13% | – |
CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -358,963 | -100.0% | -0.30% | – |
NVRO | Exit | NEVRO CORP | $0 | – | -11,000 | -100.0% | -0.36% | – |
PRSC | Exit | PROVIDENCE SVC CORP | $0 | – | -14,677 | -100.0% | -0.42% | – |
EOLS | Exit | EVOLUS INC | $0 | – | -112,590 | -100.0% | -0.83% | – |
Exit | EXACT SCIENCES CORPput | $0 | – | -14,100 | -100.0% | -0.84% | – | |
ASGN | Exit | ASGN INC | $0 | – | -30,000 | -100.0% | -0.92% | – |
WCG | Exit | WELLCARE HEALTH PLANS INC | $0 | – | -6,500 | -100.0% | -0.93% | – |
ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -200,000 | -100.0% | -1.36% | – |
Exit | INTEC PHARMA LTD JERUSALEM | $0 | – | -815,789 | -100.0% | -1.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G | 2024-01-02 |
13F-HR | 2023-11-14 |
SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.